Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a Hold rating.

Wall Street started the week on a muted note, with major indices little changed as investors looked ahead to a critical speech by Fed Chair Jerome Powell and a raft of retail earnings.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

European shares were subdued on Monday, ahead of key meetings between Ukraine, European leaders and US President Donald Trump ...

Awkward. And the problem is this backdrop is occurring while stocks have pushed ever higher, leaving the S&P 500's SPX trailing earnings per share multiple at 25.5, Emanuel notes. That's "among the ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

"This retrospective cohort study found that taking GLP-1RAs was associated with a reduced overall risk of cancer, including lower risks of endometrial, ovarian, and meningioma cancers, among patients ...

While health insurance premiums have been increasing, 2026 will see the largest hike in prices since 2018, according to KFF ...

Novo recently filed lawsuits against 14 small healthcare providers who sold compounded versions of its weight loss drug ...

NVIDIA Corporation, Novo Nordisk A/S, Shift4 Payments Inc, Hims Hers Health Inc. Read 's Market Analysis on Investing.com ...